Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | nitric oxide synthase 3 (endothelial cell) | Starlite/ChEMBL | References |
Rattus norvegicus | Nitric-oxide synthase, brain | Starlite/ChEMBL | References |
Homo sapiens | nitric oxide synthase 1 (neuronal) | Starlite/ChEMBL | References |
Homo sapiens | nitric oxide synthase 2, inducible | Starlite/ChEMBL | References |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Chlamydia trachomatis | sulfite reductase | 0.0073 | 0.2407 | 0.5 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0118 | 1 | 0.5 |
Brugia malayi | FAD binding domain containing protein | 0.0118 | 1 | 1 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.006 | 0.0151 | 0.0151 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.0118 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0118 | 1 | 0.5 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.0118 | 1 | 1 |
Trypanosoma cruzi | p450 reductase, putative | 0.0118 | 1 | 0.5 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.0118 | 1 | 0.5 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.0118 | 1 | 0.5 |
Giardia lamblia | Hypothetical protein | 0.0105 | 0.7743 | 0.5 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.0118 | 1 | 1 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.0118 | 1 | 0.5 |
Leishmania major | p450 reductase, putative | 0.0118 | 1 | 1 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.0105 | 0.7743 | 0.5 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0118 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0118 | 1 | 1 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0118 | 1 | 0.5 |
Schistosoma mansoni | cytochrome P450 reductase | 0.0118 | 1 | 1 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.0118 | 1 | 1 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0059 | 0 | 0.5 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.0118 | 1 | 1 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.0118 | 1 | 0.5 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.0118 | 1 | 0.5 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0059 | 0 | 0.5 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.0073 | 0.2407 | 0.2407 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.0118 | 1 | 1 |
Trichomonas vaginalis | sulfite reductase, putative | 0.0118 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0118 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 88 nM | In vitro inhibition of rat neuronal nitric oxide synthase | ChEMBL. | 14998342 |
IC50 (binding) | = 88 nM | In vitro inhibition of rat neuronal nitric oxide synthase | ChEMBL. | 14998342 |
IC50 (binding) | = 96.3 nM | In vitro inhibition of human neuronal nitric oxide synthase | ChEMBL. | 14998342 |
IC50 (binding) | = 96.3 nM | In vitro inhibition of human neuronal nitric oxide synthase | ChEMBL. | 14998342 |
IC50 (binding) | = 3767 nM | In vitro inhibition of human endothelial nitric oxide synthase | ChEMBL. | 14998342 |
IC50 (binding) | = 3767 nM | In vitro inhibition of human endothelial nitric oxide synthase | ChEMBL. | 14998342 |
IC50 (binding) | = 5800 nM | In vitro inhibition of human inducible nitric oxide synthase | ChEMBL. | 14998342 |
IC50 (binding) | = 5800 nM | In vitro inhibition of human inducible nitric oxide synthase | ChEMBL. | 14998342 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.